Restoring anti-oncodriver Th1 responses with dendritic cell vaccines in HER2/neu-positive breast cancer: progress and potential

HER2/neu is expressed in the majority of in situ breast cancers, but maintained in 20–30% of invasive breast cancer (IBC). During breast tumorigenesis, there is a progressive loss of anti-HER2 CD4(pos) Th1 (anti-HER2Th1) from benign to ductal carcinoma in situ, with almost complete loss in IBC. This...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Immunotherapy
Autors principals: De La Cruz, Lucy M, Nocera, Nadia F, Czerniecki, Brian J
Format: Artigo
Idioma:Inglês
Publicat: Future Medicine Ltd 2016
Matèries:
Review
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5967360/
https://ncbi.nlm.nih.gov/pubmed/27605070
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/imt-2016-0052
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars